Lovastatin

What it is

Lovastatin is a cholesterol-lowering drug, the first statin licensed anywhere. It is a fungal product, isolated from a strain of Aspergillus terreus, and is swallowed as an inactive lactone that the body opens up into the active beta-hydroxyacid. That active form blocks HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis. Tablets are 10, 20 and 40 mg. The same molecule occurs naturally in red yeast rice, where it is called monacolin K, which means a dietary supplement can deliver a statin dose without saying so.

What the research says

Lovastatin lowers LDL cholesterol by about a quarter at 20 to 40 mg a day, and the trial evidence that this prevents heart attacks is strong but has to be read separately for people who have and have not already had cardiovascular disease. In primary prevention, AFCAPS/TexCAPS randomised 6,605 people with average cholesterol and found 183 first major coronary events on placebo versus 116 on lovastatin over 5.2 years. Pooled across the statin class, the Cholesterol Treatment Trialists put the absolute benefit in low-risk people at about 11 major vascular events avoided per 1,000 over five years, and the 2022 USPSTF review puts the absolute risk difference for composite cardiovascular outcomes at -1.28%. In secondary prevention the lovastatin-specific evidence is about disease progression rather than mortality: in the Post-CABG trial aggressive LDL lowering cut graft atherosclerosis from 39% to 27% of grafts. Against this, cardiovascular mortality in primary prevention did not reach significance, muscle symptoms turned out to be no commoner than placebo in a blinded n-of-1 trial series, and statins slightly raise the risk of diabetes.

Evidence grade: Well established.

How it works

Drug class: HMG-CoA reductase inhibitor (statin)

Lovastatin blocks HMG-CoA reductase, the enzyme that converts HMG-CoA to mevalonate. That is the early, rate-limiting step of the pathway the liver uses to make cholesterol. With less cholesterol being made inside liver cells, those cells put more LDL receptors on their surface and pull LDL cholesterol out of the blood, so blood LDL falls. Production of VLDL, the particle LDL is formed from, also drops, and apolipoprotein B falls with it. (Source 1)

What it is used for

• AFCAPS/TexCAPS showed lovastatin cut first major coronary events by 37% relative, 183 versus 116 events in 6,605 people over 5.2 years. Across the class, the absolute benefit is small per person: the USPSTF puts the composite cardiovascular absolute risk difference at -1.28% and all-cause mortality at -0.35%, and the Cholesterol Treatment Trialists at about 11 major vascular events avoided per 1,000 over five years in low-risk people. Evidence: established. (Source 2)
• The lovastatin-specific trial here is Post-CABG, which used lovastatin with or without cholestyramine in 1,351 people after bypass surgery: aggressive LDL lowering cut the proportion of grafts with progression from 39% to 27% and revascularisation from 9.2% to 6.5% over four years. Mortality benefit in established disease comes from the pooled statin trials rather than from lovastatin alone: each 1 mmol/L LDL reduction cut all-cause mortality by 10% across 26 trials. Evidence: established. (Source 3)
• Lovastatin 20 to 40 mg a day lowered LDL cholesterol by 25% in AFCAPS/TexCAPS and raised HDL by 6%. This is a biomarker effect; the outcome evidence is covered by the prevention entries above. Evidence: established. (Source 2)
• The approved use in adolescents rests on lipid lowering, not on cardiovascular outcomes, and the label itself says children treated in adolescence should be re-evaluated in adulthood. No outcome trial in this age group is cited in the label. Evidence: limited. (Source 4)
• Red yeast rice contains monacolin K, which is chemically lovastatin. Measured content across 12 commercial products ranged from 0.10 to 10.09 mg of monacolin K per capsule, so the dose is unpredictable, and a third of products contained citrinin, a nephrotoxic mycotoxin. A meta-analysis of 53 RCTs found no excess musculoskeletal events, but a 2024 umbrella review rated 80% of the underlying meta-analyses as critically low confidence. Evidence: disputed. (Source 5)

Interactions

• Grapefruit juice (pharmacokinetic study): Grapefruit juice blocks CYP3A4 in the gut wall, so far less lovastatin is destroyed on first pass and much more reaches the blood. The 15-fold rise in lovastatin exposure and roughly 12-fold rise in peak level come from a deliberately heavy regimen: 10 healthy volunteers drank 200 ml of DOUBLE-strength grapefruit juice three times a day for two days, then took 80 mg of lovastatin with another 200 ml, plus two further 200 ml doses after it. Higher blood levels of a statin are what drives muscle injury, which is why the label tells people on lovastatin to avoid grapefruit juice. For what an ordinary glass does, see the label entry below. Limit: These are the numbers from a double-strength-juice regimen with an 80 mg dose, not from ordinary juice drinking. The label's second study, using one 8 oz glass of normal-strength juice, found a 1.94-fold rise instead. (Source 6)
• Grapefruit juice (how much matters: the label reports two different juice regimens) (pharmacokinetic study): The size of this interaction depends entirely on how much juice and how strong. The 15-fold rise in lovastatin exposure, and the 5-fold rise in its active metabolite, come from a deliberately extreme regimen: 200 mL of DOUBLE-strength grapefruit juice three times a day for two days, then more juice with and after a single 80 mg dose. An ordinary single 8 oz glass of normal-strength juice at breakfast for three days, with a 40 mg dose, raised lovastatin 1.94-fold and its metabolite 1.57-fold, and raised HMG-CoA reductase inhibitory activity 1.34- and 1.36-fold. The label states that amounts of juice between those two regimens have not been studied, so there is no quantity it describes as tested and safe. Limit: Do not read the 15-fold figure as the effect of a normal glass of grapefruit juice. It belongs to the double-strength, three-times-a-day regimen with an 80 mg dose. The everyday figure the label gives is about 1.9-fold for lovastatin itself, roughly an order of magnitude smaller. (Source 7)
• Red yeast rice (monacolin K) (theoretical): Red yeast rice is not a statin-like substance; it contains lovastatin itself, under the name monacolin K. Taking it alongside prescribed lovastatin is therefore double-dosing the same drug, with the extra problem that the supplement dose is not standardised. Laboratory analysis of 12 commercial products found monacolin K ranging from 0.10 to 10.09 mg per capsule. No trial has tested red yeast rice together with prescription lovastatin, so the additive-risk part of this interaction is inferred from the shared molecule rather than measured. (Source 5)
• Red yeast rice (what the trial evidence shows on its own) (clinical trial): Pooled across 53 randomised trials in 8,535 people, monacolin K was not associated with more musculoskeletal problems than control, and serious adverse events were lower. That is reassuring about red yeast rice used instead of a statin; it says nothing about taking it on top of one. Limit: The paper's own denominators do not add up: it says 8,535 subjects with 4,437 in the red yeast rice arm and 4,303 in the control arm, but those two add to 8,740, which is 205 more. We have quoted the paper exactly rather than pick a number. Read the odds ratios as the paper's results and treat the total sample size as uncertain to within a couple of hundred people. The paper also concludes that red yeast rice 'seems to be overall tolerable and safe', which is its interpretation of trial data in moderately high-cholesterol volunteers, not a statement about the unregulated products on sale. (Source 8)
• Niacin at lipid-lowering doses (1 g a day or more) and other fibrates (label): High-dose niacin, which is sold both as a prescription and as a supplement, can cause muscle injury by itself, and most of the people who developed myopathy in uncontrolled lovastatin studies were also taking ciclosporin, gemfibrozil or niacin. The label advises caution with niacin at 1 g a day or more. (Source 9)
• Alcohol (label): There is no pharmacokinetic interaction described between alcohol and lovastatin. The concern is additive liver injury: the label says the drug should be used with caution in people who drink substantial quantities of alcohol or have a history of liver disease, and active liver disease is a contraindication. Rare fatal and non-fatal liver failure has been reported with statins including lovastatin after marketing. (Source 10)
• Strong CYP3A4 inhibitors (itraconazole, ketoconazole, clarithromycin, erythromycin, HIV protease inhibitors, nefazodone, cobicistat products) (label): These block the enzyme that clears lovastatin, so blood levels rise and with them the risk of myopathy and rhabdomyolysis. Unlike most interactions, the label makes these an outright contraindication rather than a caution. (Source 11)

Stopping it

• Lovastatin has no withdrawal syndrome. The question studied is whether stopping is safe when the expected benefit no longer has time to accrue. In a randomised trial of 381 people with a life expectancy of one month to a year, stopping statins did not produce significantly more deaths within 60 days, 23.8% versus 20.3%, but the trial did not meet its prespecified non-inferiority margin, so it did not establish that stopping is as safe as continuing. (Source 12)
• In the same trial, quality of life was better in the group that stopped, and cardiovascular events were few and similar in both arms. This is one unblinded pragmatic trial in a palliative population, its non-inferiority test was not met, and it does not generalise to people with years of life expectancy. (Source 12)
• Where lovastatin is stopped because of muscle symptoms, the label records that symptoms and creatine kinase rises usually resolved when treatment was stopped promptly. The blinded StatinWISE n-of-1 trials found two thirds of people who had previously stopped statins for muscle symptoms intended to restart them after seeing their own results. (Source 13)
• Pregnancy is the one situation where the label calls for immediate discontinuation, and it gives the reasoning: atherosclerosis is a chronic process and stopping a lipid-lowering drug for the duration of a pregnancy should have little impact on long-term treatment. (Source 14)

What goes wrong

Myopathy with lovastatin is dose related: one case among 4,933 people on 20 to 40 mg daily versus four among 1,649 on 80 mg daily in the EXCEL trial, and rhabdomyolysis with rare fatalities has occurred. (Source 15)

• Official position, Certainty not rated.
• Size: 4,933 randomised to 20-40 mg and 1,649 to 80 mg daily in EXCEL.
• Who: Patients with hypercholesterolaemia, carefully monitored, with some interacting drugs excluded.
• How long: 48 weeks.
• Result: One case of myopathy among 4,933 patients on 20 to 40 mg daily (about 0.02%) and 4 among 1,649 on 80 mg daily (about 0.24%). Myopathy is defined in the label as muscle pain, tenderness or weakness with creatine kinase above ten times the upper limit of normal; it sometimes takes the form of rhabdomyolysis with or without acute renal failure, and rare fatalities have occurred.
• Funding: Manufacturer's FDA-approved label (DailyMed version 17, effective 6 May 2026); EXCEL was sponsored by the manufacturer.

The risk of myopathy/rhabdomyolysis is dose related. In a clinical study (EXCEL) in which patients were carefully monitored and some interacting drugs were excluded, there was one case of myopathy among 4933 patients randomized to lovastatin 20 to 40 mg daily for 48 weeks, and 4 among 1649 patients randomized to 80 mg daily.

Statin therapy slightly increases the risk of developing diabetes: treating 255 people for four years produces one extra case. (Source 16)

• Meta-analysis, Moderate certainty.
• Size: 13 statin trials, 91,140 participants, 4,278 developed diabetes.
• Who: Participants in randomised statin endpoint trials of more than 1,000 people and more than one year.
• How long: Mean 4 years.
• Result: Odds ratio for incident diabetes 1.09 (95% CI 1.02-1.17), I squared 11%. Treating 255 patients (95% CI 150-852) with statins for four years resulted in one extra case of diabetes. Risk was highest in trials with older participants.
• Funding: None (stated as no funding in the abstract)

Limit of this finding: The same paper tells readers not to act on this on its own: the authors write that the risk 'is low both in absolute terms and when compared with the reduction in coronary events' and that clinical practice in people at moderate or high cardiovascular risk, or with existing cardiovascular disease, should not change. One extra case of diabetes per 255 people treated for four years sits against the cardiovascular events prevented over the same period.

Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials. Meta-regression showed that risk of development of diabetes with statins was highest in trials with older participants, but neither baseline body-mass index nor change in LDL-cholesterol concentrations accounted for residual variation in risk. Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes.

People carrying two copies of the SLCO1B1 c.521C variant had about four and a half times the odds of lovastatin-related myopathy or rhabdomyolysis; the matching association in atorvastatin users did not reach statistical significance. (Source 17)

• Case-control study, Low certainty.
• Size: 233 statin-induced myopathy plus rhabdomyolysis cases matched to 2,342 controls.
• Who: Participants in the Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort taking lovastatin, atorvastatin or simvastatin.
• How long: Retrospective cohort-based case-control analysis.
• Result: Lovastatin users, CC versus TT: odds ratio 4.49 (95% CI 1.68-10.80, P=0.001). For atorvastatin the association was not significant (OR 2.00, 95% CI 0.44-6.59, P=0.30).
• Funding: not stated in the abstract.

Limit of this finding: This is a genetic case-control analysis inside a cohort, not a trial, so it shows an association and not a cause. The atorvastatin figure (odds ratio 2.00) looks like a doubling but its confidence interval runs from 0.44 to 6.59 and the p-value is 0.30, which means the study could not tell it apart from no effect at all. The authors themselves say only that the simvastatin association 'may also extend to lovastatin' and that more data are needed for atorvastatin.

For lovastatin users, homozygous carriers of the C allele were also at increased risk of statin-induced myopathy + rhabdomyolysis (CC vs. TT, OR 4.49, 95% CI 1.68-10.80

Rare fatal and non-fatal liver failure has been reported after marketing in people taking statins including lovastatin. (Source 10)

• Official position, Very low certainty.
• Size: Not quantified; spontaneous postmarketing reports.
• Who: People taking statins including lovastatin.
• How long: Postmarketing surveillance of unknown duration.
• Result: No rate can be derived from spontaneous reports. The label instructs interrupting therapy if serious liver injury with symptoms, hyperbilirubinaemia or jaundice occurs, and not restarting if no alternative cause is found. Active liver disease is a contraindication.
• Funding: Manufacturer's FDA-approved label (DailyMed version 17, effective 6 May 2026); spontaneous reports cannot establish frequency or causation.

There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including lovastatin.

Red yeast rice supplements, which contain lovastatin as monacolin K, delivered anywhere from 0.10 to 10.09 mg of it per capsule, and a third of tested products contained the mycotoxin citrinin. (Source 5)

• Survey study, Moderate certainty.
• Size: 12 commercial red yeast rice formulations, each labelled 600 mg per capsule.
• Who: Commercial dietary supplement products, analysed by HPLC with mass spectrometry.
• How long: Analyses performed between August 2006 and June 2008.
• Result: Total monacolins 0.31 to 11.15 mg per capsule; monacolin K (lovastatin) 0.10 to 10.09 mg per capsule; monacolin KA 0.00 to 2.30 mg per capsule. Four of the 12 products had elevated citrinin, a mycotoxin that is nephrotoxic in animals.
• Funding: Laboratory analyses were conducted by ConsumerLab.com.

There was marked variability in the 12 RYR products in total monacolins (0.31-11.15 mg/capsule), monacolin K (lovastatin) (0.10-10.09 mg/capsule), and monacolin KA (0.00-2.30 mg/capsule). Four products had elevated levels of citrinin.

A 2024 umbrella review found the safety evidence for red yeast rice is mostly reassuring but rests on meta-analyses of low or critically low methodological confidence, with signals for liver enzymes and uric acid. (Source 18)

• Review of reviews, Low certainty.
• Size: 15 meta-analyses comprising 186 randomised trials (164 unique)
• Who: Participants in randomised trials of red yeast rice preparations.
• How long: Varied across the included meta-analyses.
• Result: 3 of 15 meta-analyses (20%) had low and 12 (80%) critically low confidence on AMSTAR 2. Of 61 associations, 10 (16.4%) showed a protective effect, 5 (8.2%) an increased risk relating to uric acid, alanine transaminase and aspartate transaminase, and 46 (75.4%) no significant difference. Credibility was moderate for 21, low for 34 and very low for 6.
• Funding: not stated in the abstract.

while 5 (8.2%) indicated an increased risk of adverse health outcomes related to uric acid, alanine transaminase and aspartate transaminase levels. The other 46 (75.4%) associations showed no significant difference between the use of RYR preparations and control treatments.

What the evidence supports

In people with no symptomatic cardiovascular disease and average cholesterol, lovastatin reduced first major coronary events from 183 to 116 over 5.2 years. (Source 2)

• Randomized trial, High certainty.
• Size: 6,605 participants (5,608 men, 997 women)
• Who: Adults without clinically evident atherosclerotic cardiovascular disease, average total and LDL cholesterol (mean LDL 150 mg/dL) and below-average HDL (36 mg/dL in men, 40 in women)
• How long: Average follow-up 5.2 years.
• Result: First acute major coronary events 183 on placebo vs 116 on lovastatin (relative risk 0.63, 95% CI 0.50-0.79, P<.001); myocardial infarction 95 vs 57 (RR 0.60, 0.43-0.83, P=.002); coronary revascularisation 157 vs 106 (RR 0.67, 0.52-0.85, P=.001). Lovastatin 20-40 mg daily reduced LDL-C by 25% and raised HDL-C by 6%.
• Funding: AFCAPS/TexCAPS was sponsored by Merck, the manufacturer of lovastatin.

Limit of this finding: One oddity in the companion baseline block from the same abstract, reproduced as published: JAMA reports 'median (SD) triglyceride levels were 1.78 (0.86) mmol/L', pairing a median with a standard deviation, which do not belong together. It affects only the description of the starting population, not the event counts above. The trial was also sponsored by Merck, the manufacturer.

After an average follow-up of 5.2 years, lovastatin reduced the incidence of first acute major coronary events (1 83 vs 116 first events; relative risk [RR], 0.63; 95% confidence interval [CI], 0.50-0.79; P<.001), myocardial infarction (95 vs 57 myocardial infarctions; RR, 0.60; 95% CI, 0.43-0.83; P=.002), unstable angina (87 vs 60 first unstable angina events; RR, 0.68; 95% CI, 0.49-0.95; P=.02), coronary revascularization procedures (157 vs 106 procedures; RR, 0.67; 95% CI, 0.52-0.85; P=.001)

A Cochrane review of 18 primary-prevention trials in 56,934 people found statins reduced all-cause mortality and major cardiovascular events. (Source 19)

• Systematic review, Moderate certainty.
• Size: 18 randomised controlled trials (19 trial arms), 56,934 participants.
• Who: Adults with no history of cardiovascular disease, or trials in which 10% or fewer had such a history.
• How long: Minimum one year of treatment, six months follow-up.
• Result: All-cause mortality OR 0.86 (95% CI 0.79 to 0.94); fatal and non-fatal CVD RR 0.75 (0.70 to 0.81); fatal and non-fatal CHD RR 0.73 (0.67 to 0.80); fatal and non-fatal stroke RR 0.78 (0.68 to 0.89); revascularisation RR 0.62 (0.54 to 0.72). The review notes evidence of heterogeneity of effects on cholesterol.
• Funding: Cochrane review, independent.

Limit of this finding: This review also states that there was no evidence of any serious harm from statins. That is not the settled position: a 2010 meta-analysis of 13 trials in 91,140 people, also quoted in this write-up, found a 9% higher rate of new diabetes (one extra case per 255 people treated for four years). The two are recorded side by side under disagreements rather than either being presented as the answer.

All-cause mortality was reduced by statins (OR 0.86, 95% CI 0.79 to 0.94); as was combined fatal and non-fatal CVD RR 0.75 (95% CI 0.70 to 0.81), combined fatal and non-fatal CHD events RR 0.73 (95% CI 0.67 to 0.80) and combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.68 to 0.89).

In low-risk people the absolute benefit of statin treatment is about 11 major vascular events avoided per 1,000 people over five years for each 1 mmol/L of LDL lowering. (Source 20)

• Meta-analysis, High certainty.
• Size: 27 trials: 22 of statin versus control (134,537 participants) and 5 of more versus less statin (39,612)
• Who: Participants stratified by baseline 5-year major vascular event risk; this figure applies to those under 10%.
• How long: Median follow-up 4.8 years (statin vs control) and 5.1 years (more vs less)
• Result: Absolute reduction of about 11 major vascular events per 1,000 over 5 years per 1 mmol/L LDL reduction in people with 5-year risk below 10%. Overall rate ratio for major vascular events 0.79 (95% CI 0.77-0.81) per 1.0 mmol/L reduction.
• Funding: British Heart Foundation, UK Medical Research Council, Cancer Research UK and other non-commercial funders.

In individuals with 5-year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years.

The 2022 USPSTF evidence review gives the absolute numbers for primary prevention: all-cause mortality falls by 0.35 percentage points and composite cardiovascular outcomes by 1.28 percentage points. (Source 21)

• Systematic review, Moderate certainty.
• Size: 22 trials, 90,624 participants, with 3 observational studies (417,523) for harms.
• Who: Adults without prior cardiovascular events but at increased cardiovascular risk.
• How long: 6 months to 6 years of follow-up.
• Result: All-cause mortality RR 0.92 (95% CI 0.87 to 0.98), absolute risk difference -0.35% (-0.57% to -0.14%); stroke RR 0.78, ARD -0.39%; myocardial infarction RR 0.67, ARD -0.85%; composite cardiovascular outcomes RR 0.72, ARD -1.28% (-1.61% to -0.95%). Data for people over 75 were sparse.
• Funding: Prepared for the US Preventive Services Task Force under contract to AHRQ (government-funded)

Statins were significantly associated with decreased risk of all-cause mortality (risk ratio [RR], 0.92 [95% CI, 0.87 to 0.98]; absolute risk difference [ARD], -0.35% [95% CI, -0.57% to -0.14%]), stroke (RR, 0.78 [95% CI, 0.68 to 0.90]; ARD, -0.39% [95% CI, -0.54% to -0.25%]), myocardial infarction (RR, 0.67 [95% CI, 0.60 to 0.75]; ARD, -0.85% [95% CI, -1.22% to -0.47%]), and composite cardiovascular outcomes (RR, 0.72 [95% CI, 0.64 to 0.81]; ARD, -1.28% [95% CI, -1.61% to -0.95%])

In people who had already had bypass surgery, lowering LDL aggressively with lovastatin cut the proportion of grafts with progressing atherosclerosis from 39% to 27% and revascularisation from 9.2% to 6.5%. (Source 3)

• Randomized trial, Moderate certainty.
• Size: 1,351 patients, two-by-two factorial design.
• Who: People 1 to 11 years after coronary bypass surgery with LDL cholesterol 130 to 175 mg/dL and at least one patent vein graft.
• How long: Repeat angiography an average of 4.3 years after baseline; revascularisation rates over four years.
• Result: Mean LDL 93-97 mg/dL on aggressive treatment versus 132-136 mg/dL on moderate (P<0.001). Mean percentage of grafts with progression 27% versus 39% (P<0.001). Revascularisation over four years 6.5% versus 9.2% (P=0.03), 29% lower. Low-dose warfarin made no difference to angiographic outcome.
• Funding: National Heart, Lung and Blood Institute sponsored multicentre trial; funding detail not stated in the abstract.

The mean percentage of grafts with progression of atherosclerosis was 27 percent for patients whose LDL cholesterol level was lowered with aggressive treatment, and 39 percent for those who received moderate treatment (P<0.001). There was no significant difference in angiographic outcome between the warfarin and placebo groups. The rate of revascularization over four years was 29 percent lower in the group whose LDL cholesterol level was lowered aggressively than in the group receiving moderate treatment (6.5 percent vs. 9.2 percent, P= 0.03).

Pooling 21 statin-versus-control trials with 5 more-versus-less-intensive statin trials, 26 in all and about 170,000 people, each 1 mmol/L of LDL reduction cut all-cause mortality by 10%, driven by fewer coronary deaths, with no effect on stroke deaths or cancer. (Source 22)

• Meta-analysis, High certainty.
• Size: 26 trials: 5 of more versus less intensive statin (39,612) and 21 of statin versus control (129,526)
• Who: Participants in randomised statin trials of at least 1,000 people and at least two years of treatment, including those with established vascular disease.
• How long: Median follow-up 5.1 years (more vs less) and 4.8 years (statin vs control)
• Result: All-cause mortality RR 0.90 (95% CI 0.87-0.93; p<0.0001) per 1.0 mmol/L LDL reduction; coronary heart disease deaths RR 0.80 (99% CI 0.74-0.87); no significant effect on stroke deaths (RR 0.96, 0.84-1.09; p=0.5) or cancer incidence (RR 1.00, 0.96-1.04; p=0.9).
• Funding: UK Medical Research Council, British Heart Foundation and other non-commercial funders.

Limit of this finding: 'All 26 trials' in the quoted sentence is the combined set: 21 trials of a statin against control (129,526 people) plus 5 trials of a more intensive against a less intensive statin regimen (39,612 people). It is not 26 intensive-therapy trials, and the 10% mortality figure is not an intensive-versus-standard result. Note too that the paper mixes interval widths in one list: the all-cause mortality interval is a 95% CI, while the coronary-death and other-vascular-death intervals are 99% CIs.

Across all 26 trials, all-cause mortality was reduced by 10% per 1·0 mmol/L LDL reduction (RR 0·90, 95% CI 0·87-0·93; p<0·0001), largely reflecting significant reductions in deaths due to coronary heart disease (RR 0·80, 99% CI 0·74-0·87; p<0·0001) and other cardiac causes (RR 0·89, 99% CI 0·81-0·98; p=0·002), with no significant effect on deaths due to stroke (RR 0·96, 95% CI 0·84-1·09; p=0·5) or other vascular causes (RR 0·98, 99% CI 0·81-1·18; p=0·8). No significant effects were observed on deaths due to cancer or other non-vascular causes (RR 0·97, 95% CI 0·92-1·03; p=0·3) or on cancer incidence (RR 1·00, 95% CI 0·96-1·04; p=0·9), even at low LDL cholesterol concentrations.

What the evidence does not support

In primary prevention, statins did not significantly reduce cardiovascular mortality, and did not significantly increase serious adverse events, myalgias or liver enzyme rises. (Source 21)

• Systematic review, Moderate certainty.
• Size: 22 trials, 90,624 participants.
• Who: Adults without prior cardiovascular events.
• How long: 6 months to 6 years.
• Result: Cardiovascular mortality RR 0.91 (95% CI 0.81 to 1.02), absolute risk difference -0.13%, not statistically significant. Serious adverse events RR 0.97 (0.93 to 1.01); myalgias RR 0.98 (0.86 to 1.11); raised alanine aminotransferase RR 0.94 (0.78 to 1.13); diabetes overall RR 1.04 (0.92 to 1.19).
• Funding: Prepared for the US Preventive Services Task Force under AHRQ contract.

the association with cardiovascular mortality was not statistically significant (RR, 0.91 [95% CI, 0.81 to 1.02]; ARD, -0.13%)

In people who had previously stopped statins because of muscle symptoms, a series of blinded n-of-1 trials found no difference in muscle symptoms between statin and placebo periods. (Source 13)

• Randomized trial, Moderate certainty.
• Size: 200 randomised, 151 in the primary analysis.
• Who: Primary care patients across 50 UK sites who had recently stopped or were considering stopping statins because of muscle symptoms.
• How long: Six double-blinded two-month treatment periods per participant.
• Result: Mean difference in muscle symptom score, statin minus placebo, -0.11 (95% CI -0.36 to 0.14; P=0.40) on a 0-10 scale. Withdrawals for intolerable muscle symptoms: 18 (9%) during a statin period and 13 (7%) during a placebo period.
• Funding: NIHR Health Technology Assessment programme (independent, UK government)

Overall, no difference in muscle symptom scores was found between the statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; P=0.40))

In the 8,245-patient EXCEL trial no individual adverse experience occurred significantly more often on lovastatin than on placebo. (Source 23)

• Official position, Certainty not rated.
• Size: 8,245 patients.
• Who: Patients with hypercholesterolaemia, total cholesterol 240 to 300 mg/dL.
• How long: 48 weeks, randomised, double-blind, parallel.
• Result: Adverse experiences reported as possibly, probably or definitely drug-related in at least 1% of any group are tabulated in the label; for no event was the incidence on drug and placebo statistically different.
• Funding: Reported in the manufacturer's FDA-approved label (DailyMed version 17, effective 6 May 2026); EXCEL was a Merck-sponsored trial.

Lovastatin was compared to placebo in 8,245 patients with hypercholesterolemia (total-C 240 to 300 mg/dL [6.2 to 7.8 mmol/L]) in the randomized, double-blind, parallel, 48-week EXCEL study. Clinical adverse experiences reported as possibly, probably or definitely drug-related in ≥1% in any treatment group are shown in the table below. For no event was the incidence on drug and placebo statistically different.

Where the research disagrees

Whether muscle symptoms people report on statins are caused by the statin

• Lupin Pharmaceuticals, in the FDA-approved lovastatin label (DailyMed version 17, effective 6 May 2026), Regulatory position drawing on the 48-week EXCEL trial and postmarketing reports; the trial figures are 1 case in 4,933 on 20-40 mg and 4 in 1,649 on 80 mg: Lovastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). (Source 15)
• Herrett and colleagues, the StatinWISE investigators, 2021 BMJ, Series of 200 randomised, placebo-controlled n-of-1 trials in UK primary care, 151 analysed; tested atorvastatin 20 mg, not lovastatin: Overall, no difference in muscle symptom scores was found between the statin and placebo periods (mean difference statin minus placebo -0.11, 95% confidence interval -0.36 to 0.14; P=0.40)) (Source 13)

Whether red yeast rice is a safe alternative to a prescription statin

• Fogacci and colleagues, 2019 meta-analysis of 53 randomised trials in Pharmacological Research, Meta-analysis of safety data from 53 randomised controlled trials, 112 treatment arms; the paper states 8,535 subjects but its own arm sizes, 4,437 and 4,303, add to 8,740: Monacolin K administration was not associated with increased risk of MuD (odds ratio (OR) = 0.94, 95% confidence interval (CI) 0.53,1.65). (Source 8)
• Gordon and colleagues, 2010 Archives of Internal Medicine product analysis, Laboratory analysis of 12 commercial products by HPLC with mass spectrometry, showing a hundred-fold range in monacolin K content and citrinin in a third of products: Although studies have suggested that some formulations of RYR may be effective and safe for lipid lowering, monacolin levels are not standardized among marketed products and are generally not published on labels. (Source 24)

Whether statins used for primary prevention cause any serious harm. Two reviews in this write-up, both verbatim and both from 2010-2013, point opposite ways

• Taylor and colleagues, 2013 Cochrane review of statins for primary prevention, Systematic review of 18 randomised trials, 19 trial arms, 56,934 participants: There was no evidence of any serious harm caused by statin prescription. (Source 19)
• Sattar and colleagues, 2010 collaborative meta-analysis in the Lancet, Meta-analysis of 13 randomised statin endpoint trials, 91,140 participants, mean 4 years: Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials. (Source 16)
• Sattar and colleagues, in the same paper, on what to do about it, The same 13-trial meta-analysis; this is the authors' own interpretation, not a separate result: Statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change. (Source 25)

How much

• Reference intake: There is no reference intake for a prescription drug; the dose is set by the prescriber. As a regulatory position, the FDA-approved label (DailyMed version 17, effective 6 May 2026) records, for ADULT patients, a usual starting dose of 20 mg once a day with the evening meal and a dosing range of 10 to 80 mg a day, taken with meals. Separate, lower figures apply to adolescents and to people on interacting drugs. (Source 4)
• Upper limit: The label's stated maxima, a position and not a trial finding, are tiered and are spread across three parts of label section 2. For ADULTS the maximum is 80 mg a day (reference lova-label-dose). For adolescents aged 10 to 17 with heterozygous familial hypercholesterolaemia it is 40 mg a day (reference lova-label-dose-adolescent). With danazol, diltiazem, dronedarone or verapamil it is 20 mg a day, and with amiodarone 40 mg a day (reference lova-label-dose-interacting, the source quoted here). The 80 mg figure is the adult ceiling only and is not a universal maximum. (Source 26)
• Studied: AFCAPS/TexCAPS gave 20 to 40 mg daily, or placebo, to 6,605 people for an average of 5.2 years. (Source 2)
• Studied: The 48-week EXCEL trial randomised 8,245 people to placebo or lovastatin at 20 mg daily, 40 mg daily, or 20 mg twice daily and higher, which is where the dose-related myopathy figures come from. (Source 23)
• Studied: The Post-CABG trial used lovastatin with cholestyramine added if needed, aiming for aggressive versus moderate LDL targets, in 1,351 people over an average 4.3 years. (Source 3)
• Studied: The grapefruit interaction study gave 10 healthy volunteers 200 ml of double-strength grapefruit juice or water three times a day for two days, then 80 mg of lovastatin with a further 200 ml, and 200 ml again at half an hour and an hour and a half afterwards. (Source 27)

A common belief, and what the research shows

The belief: Red yeast rice is a natural alternative to a statin, so it carries none of a statin's risks.

What the research shows: Red yeast rice does not resemble a statin; it contains one. Laboratory analysis of 12 commercial products found “monacolin K (lovastatin) (0.10-10.09 mg/capsule)”, a hundred-fold spread in a drug dose nobody declared, and “Four products had elevated levels of citrinin.” Citrinin is a mycotoxin that is nephrotoxic in animals. The 2010 analysis noted that “monacolin levels are not standardized among marketed products and are generally not published on labels”. Randomised-trial safety data for red yeast rice on its own are reassuring, but taking it alongside prescribed lovastatin means two doses of the same molecule, one of them unmeasured.

Questions and answers

What is it?

Lovastatin is a cholesterol-lowering tablet and the first statin ever licensed. It is a fungal product, purified from a strain of Aspergillus terreus. The tablet contains an inactive lactone which the body converts into the active beta-hydroxyacid; that is the part that blocks cholesterol synthesis. Tablets come as 10, 20 and 40 mg. The identical molecule occurs in red yeast rice, where it is called monacolin K. (Source 28)

What does it do in the body?

It blocks HMG-CoA reductase, the enzyme that turns HMG-CoA into mevalonate. That is the early, rate-limiting step in making cholesterol. With less cholesterol being made inside liver cells, those cells increase their LDL receptors and pull more LDL out of the blood, so blood LDL falls, typically by about a quarter at 20 to 40 mg a day. Production of VLDL also drops and apolipoprotein B falls with it. (Source 1)

Is it good or bad for you?

It depends on starting risk. In people who have never had a cardiovascular event, lovastatin cut first major coronary events from 183 to 116 over 5.2 years in 6,605 people, but the absolute gain per person is modest: the USPSTF puts the composite cardiovascular absolute risk difference at -1.28% and cardiovascular mortality was not significantly reduced. Across 26 pooled statin trials, 21 of statin against control and 5 of a more intensive against a less intensive regimen, each 1 mmol/L of LDL lowering was followed by a 10% fall in all-cause mortality; that is a class figure, not a lovastatin-specific one. The harms are real but uncommon, and muscle symptoms in particular were no commoner than placebo when tested blind. (Source 22)

How do you get more of it?

Lovastatin is prescription-only, and the amount is set by the prescriber; for adults the label records a usual start of 20 mg with the evening meal within a range of 10 to 80 mg a day, with 80 mg a day the adult ceiling. Lower ceilings apply to adolescents (40 mg a day) and to people taking certain interacting medicines (20 mg a day with danazol, diltiazem, dronedarone or verapamil; 40 mg a day with amiodarone). There is one unregulated route to the same molecule: red yeast rice supplements contain monacolin K, which is lovastatin. That is not a controlled way to get it. Measured content across 12 commercial products ran from 0.10 to 10.09 mg per capsule, a hundred-fold spread, and a third of the products also contained citrinin. (Source 4)

If it is harmful, what reduces it?

If lovastatin is causing muscle problems the step described in the label is to stop it immediately; in most cases muscle symptoms and creatine kinase rises resolved when treatment was stopped promptly. For liver injury the label says to interrupt therapy and not restart if no other cause is found. Where the issue is that benefit no longer outweighs burden, a randomised trial of 381 people with limited life expectancy found no significant difference in 60-day deaths after stopping and slightly better quality of life, though that trial did not meet its prespecified non-inferiority margin. (Source 12)

Why might someone be low in it or missing it?

Nobody is deficient in lovastatin; it is a drug, not a nutrient. Reasons someone is not on it include never having been prescribed one, stopping for muscle symptoms, or a contraindication: active liver disease or unexplained persistent transaminase rises, pregnancy and breastfeeding, or taking a strong CYP3A4 inhibitor, which the label makes an outright contraindication. People carrying two copies of the SLCO1B1 c.521C variant are at higher risk of statin muscle injury and may have been switched away. (Source 14)

Which whole foods contain it or feed it?

One food contains lovastatin: red yeast rice, the fermentation product of Monascus purpureus on rice, where lovastatin appears as monacolin K. It is sold as a supplement and its content is not standardised. The other food that matters does the opposite, grapefruit juice, which blocks the enzyme that clears lovastatin and raised exposure 15-fold in a crossover study. The label also directs that lovastatin tablets be given with meals. (Source 24)

What happens if you do not have it?

Not taking lovastatin does not cause a deficiency state; it means forgoing a reduction in cardiovascular risk whose size depends on your starting risk. In a 6,605-person primary prevention trial, 183 people on placebo had a first major coronary event against 116 on lovastatin over 5.2 years. For low-risk people the pooled figure is about 11 major vascular events avoided per 1,000 over five years for each 1 mmol/L of LDL lowering. In people with established disease the stakes are higher, since each 1 mmol/L reduction cut all-cause mortality by 10% across 26 trials. (Source 20)

How can you test for it?

The test that matters is a fasting lipid profile: total cholesterol, LDL, HDL and triglycerides, measured before starting and then periodically. The label notes LDL can be estimated from the other three only when triglycerides are under 400 mg/dL, above which ultracentrifugation is needed, so the usual calculated LDL is unreliable in people with high triglycerides. Creatine kinase may be checked when starting or increasing the dose, but the label is explicit that such monitoring gives no assurance of preventing myopathy. Liver enzymes are checked because of the liver-injury signal. (Source 29)

References

1. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
2. JAMA. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.. 1998. PMID 9613910, DOI 10.1001/jama.279.20.1615. Read the source
3. The New England journal of medicine. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.. 1997. PMID 8992351, DOI 10.1056/NEJM199701163360301. Read the source
4. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17) - DOSAGE AND ADMINISTRATION, Adult Patients. 2026. Read the source
5. Archives of internal medicine. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!. 2010. PMID 20975018, DOI 10.1001/archinternmed.2010.382. Read the source
6. Clinical pharmacology and therapeutics. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.. 1998. PMID 9585793, DOI 10.1016/S0009-9236(98)90034-0. Read the source
7. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
8. Pharmacological research. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials.. 2019. PMID 30844537, DOI 10.1016/j.phrs.2019.02.028. Read the source
9. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
10. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
11. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
12. JAMA internal medicine. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.. 2015. PMID 25798575, DOI 10.1001/jamainternmed.2015.0289. Read the source
13. BMJ (Clinical research ed.). Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials.. 2021. PMID 33627334, DOI 10.1136/bmj.n135. Read the source
14. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
15. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
16. Lancet (London, England). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.. 2010. PMID 20167359, DOI 10.1016/S0140-6736(09)61965-6. Read the source
17. Clinical pharmacology and therapeutics. Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.. 2021. PMID 34114646, DOI 10.1002/cpt.2337. Read the source
18. Journal of integrative medicine. Associations between the use of red yeast rice preparations and adverse health outcomes: An umbrella review of meta-analyses of randomized controlled trials.. 2024. PMID 38413255, DOI 10.1016/j.joim.2024.01.008. Read the source
19. The Cochrane database of systematic reviews. Statins for the primary prevention of cardiovascular disease.. 2013. PMID 23440795, DOI 10.1002/14651858.CD004816.pub5. Read the source
20. Lancet (London, England). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.. 2012. PMID 22607822, DOI 10.1016/S0140-6736(12)60367-5. Read the source
21. JAMA. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.. 2022. PMID 35997724, DOI 10.1001/jama.2022.12138. Read the source
22. Lancet (London, England). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.. 2010. PMID 21067804, DOI 10.1016/S0140-6736(10)61350-5. Read the source
23. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
24. Archives of internal medicine. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!. 2010. PMID 20975018, DOI 10.1001/archinternmed.2010.382. Read the source
25. Lancet (London, England). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (authors' interpretation). 2010. PMID 20167359, DOI 10.1016/S0140-6736(09)61965-6. Read the source
26. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17) - DOSAGE AND ADMINISTRATION, dose ceilings with interacting drugs. 2026. Read the source
27. Clinical pharmacology and therapeutics. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. (study methods: the juice and lovastatin regimen). 1998. PMID 9585793, DOI 10.1016/S0009-9236(98)90034-0. Read the source
28. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source
29. Lupin Pharmaceuticals, Inc. / DailyMed (U.S. National Library of Medicine). LOVASTATIN tablet - FDA prescribing information (DailyMed SPL, version 17). 2026. Read the source